Mauersberger, Carina http://orcid.org/0000-0003-4241-8854
Sager, Hendrik B. http://orcid.org/0000-0002-0197-6553
Wobst, Jana
Dang, Tan An
Lambrecht, Laura
Koplev, Simon
Stroth, Marlène
Bettaga, Noomen
Schlossmann, Jens
Wunder, Frank
Friebe, Andreas
Björkegren, Johan L. M.
Dietz, Lisa
Maas, Sanne L. http://orcid.org/0000-0003-1423-8901
van der Vorst, Emiel P. C. http://orcid.org/0000-0001-5771-6278
Sandner, Peter http://orcid.org/0000-0003-2977-7553
Soehnlein, Oliver
Schunkert, Heribert http://orcid.org/0000-0001-6428-3001
Kessler, Thorsten http://orcid.org/0000-0003-3326-1621
Article History
Received: 27 January 2022
Accepted: 27 October 2022
First Online: 12 December 2022
Competing interests
: H.S. has received personal fees from MSD Sharp & Dohme, Amgen, Bayer Vital GmbH, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Servier, Brahms, Bristol Myers Squibb, Medtronic, Sanofi Aventis, Synlab, Pfizer and Vifor T as well as grants and personal fees from AstraZeneca that are unrelated to the submitted work. H.S. and T.K. are named inventors on a patent application for the prevention of restenosis after angioplasty and stent implantation (patent applicants: Klinikum rechts der Isar, German Heart Centre Munich; inventors: T. Kessler, A. Kastrati, H. Schunkert; application no. PCT/EP2021/053116; status: pending), which is unrelated to the submitted work. T.K. received lecture fees from Bayer HealthCare Pharmaceuticals. L.D., F.W. and P.S. are full-time employees of Bayer HealthCare Pharmaceuticals. The other authors declare no competing interests.